EIN 91-0653422

Benaroya Research Institute at Virginia Mason

IRS 501(c) type
501(c)(3)
Num. employees
360
Year formed
1956
Most recent tax filings
2022-06-01
Description
Advancing immune system disease science. Quick translation from basic research lab to patient clinic. Also highlighting ITN advancements.
Total revenues
$94,861,276
2022
Total expenses
$83,785,554
2022
Total assets
$100,143,058
2022
Num. employees
360
2022

Program areas at Benaroya Research Institute at Virginia Mason

Interventional immunologyinterventional immunology and advancements of the immune tolerance network (itn) are highlighted below.funding for the immune tolerance network (itn) was originally awarded to bri's dr. jerry nepom in 2014 from the national Institute of allergy and infectious disease (niaid) of the national institutes of health (nih) and renewed for a second grant cycle in 2021. The new 7-year award, totaling ~$27 million annually supports the itn, a Research consortium established in 1999 with a primary focus on the development of new tolerogenic approaches for the treatment and prevention of disease in three clinical areas: asthma and allergic diseases; autoimmune diseases; and immune-mediated rejection of transplanted solid organs, tissues and cells. As the prime recipient of this grant, bri is responsible for the management of the overall grant from niaid; including oversight of all aspects of the network's infrastructure.the major activities during this time period were diverse, but continued to center on preserving the itn's cohesive project focused environment and its framework which has proven so successful in the management of a large cooperative agreement grant. Key outcomes during this time period include the following: 1. Funding renewal: the itn grant was renewed starting february 2021. The focus of the renewal continued to be adherence to the itn mission "to advance the clinical application of immune tolerance by performing high quality clinical trials of emerging therapeutics based upon well-established testable mechanistic hypotheses." Itn leadership structure, previously consolidated at bri, ucsf and mgh, was restructured as the itn leadership group (lg). Under the new structure, dr. jerry nepom continued his role as principal investigator, with dr. bill st clair (duke university), who had served as itn deputy director, clinical affairs since 2014, was added as the itn's co-director. Drs. Nepom and st clair oversee the lg that includes academic experts from university of Michigan , emory university and brigham and women's hospital (bwh) each representing one of the itn therapeutic areas (autoimmunity, transplantation and allergy) and two academic immunologists (uscf and bwh) with expertise in cellular and systems immunology, and bioinformatics. The lg is responsible for coordination across the network activities, tracking progress with respect to network goals, and developing strategies to meet network objectives. 2. Cross network integration: the covid 19 pandemic presented a shift in itn infrastructure as personnel moved to a wfh model. This shift was largely seamless due to past focus on careful planning and emphasis on collaboration across the itn's major centers. No changes to existing network integration were needed during this time period as the current model, strengthened by the itn lg, continued to successfully support the overall itn program. Establishing new relationships and vital connections within the Research community continued successfully. 3. Operations and clinical trial support: the itn program team at bri issued 203 subawards in 2021 and 233 in 2022 in support of 25 active itn clinical trials and numerous supporting itn mechanistic trials. 4. Supplemental funding / partnerships: itn central administration continued to focus on identifying additional opportunities for supplemental funding and/or funding partnerships. In 2021, the itn continued to support the contracting component for several niaid sponsored covid-19 clinical trials funded through administrative supplements: (a) supplemental funding opportunities: the itn program team at bri submitted four supplemental funding requests in 2021 which were carried over into 2022. These supplements account for an additional $18.3m to the itn program at bri during this time period. (b) partnerships: in 2021, the itn continued its relationship with two pharmaceutical partners for partial funding of two ongoing itn studies. With the successful completion of one partnership study at the end of 2021, the itn continued its partnership with the remaining pharmaceutical company throughout 2022. Niaid is the clinical sponsor on both of these trials. 5. Publication activity: in total for 2021 and 2022, 58 itn publications were published in prestigious Research journals and were presented at domestic and international Research conferences. These publications represented itn Research in all therapeutic focus areas of the itn: autoimmunity, transplantation and allergy.type one diabetes researchbri is dedicated to seeking ways to eliminate type 1 diabetes by finding ways to predict the disease before clinical symptoms occur and to identify therapies that prevent, reverse and intervene in the disease at any stage. Bri is an international leader in type 1 diabetes Research and has investigated it for more than 35 years, starting with identification of a genetic marker for the disease. Bri supports type 1 diabetes trialnet, a national institutes of health funded clinical trial network for type 1 diabetes prevention and early treatment, serving as the trialnet hub of 18 clinical centers worldwide working with more than 150 screening and clinical Research sites. Teplizumab can delay t1d - scientists led by carla greenbaum, md, director of bri's diabetes Research program, and the trialnet consortium spent decades trying to determine how to stop t1d before it starts. Their hard work came to fruition in november, when the fda approved a therapy that marked a milestone in preventing t1d. The therapy, teplizumab, can delay t1d for a median of two years. It impacts t cells in the immune system, dampening the immune response. In t1d, the immune system is attacking the insulin-producing beta cells; teplizumab helps slow the attack on these cells.bri is a clinical center for the trialnet pathway to prevention study, screening relatives of people with type 1 diabetes to find out if these family members are at risk for developing diabetes. Relatives of people with type 1 diabetes are at 15 times greater risk of developing type 1 diabetes. Those who qualify have the opportunity to enroll in a prevention trial. Those with two or more autoantibodies are closely monitored for early detection of type 1 diabetes. Close monitoring of at-risk family members can reduce the chances of being diagnosed in diabetic ketoacidosis (dka), a potentially life-threatening complication. In 2022, bri led Research that developed engineered regulatory t cells (tregs) as a potential t1d treatment, to stop the immune cell attack on the pancreas that leads to t1d. Dr. buckner and her lab, along with dr. david rawlings, director of the center for immunity and immunotherapy at seattle children's Research Institute, have been working toward this goal for more than ten years. The buckner lab demonstrated that these islet-specific engtregs have the capacity to suppress t cells attacking the pancreas using cell culture models of cells isolated from individuals with t1d. Dr. rawlings and his team then demonstrated that these islet-specific engtregs target the pancreas and prevent diabetes in a mouse model of diabetes. Together these findings demonstrate therapeutic potential for islet-specific engtregs in human t1d.a study led by cate speake, phd, found that interventions involving il-6-targeted therapies impacted immune outcomes in people with t1d, depending on the target of the therapeutic interventions (il-6 versus il-6r) and drug concentration. The findings indicate that these therapies drive t cell changes that can influence therapeutic outcomes.testing covid vaccines and viral infections in vulnerable populations in 2022, bri received new funding from the national institutes of health (nih) to study respiratory viral infections in vulnerable populations. The $11.4 million-dollar u19 grant supports collaborative projects involving multiple institutions. The five-year awarded project, led by carmen mikacenic, md, and matt altman, md, mphil, will study immune system changes upon infection with acute respiratory viral infections (arvi) in vulnerable populations like children with allergies, asthma and obesity and adults with rheumatoid arthritis. Given the collaborative nature of the grant, bri will then share its longitudinal findings with the human immunology project consortium (hipc), a network of researchers creating a public resource that characterizes the diverse states of the human immune system.also in 2022, studies in the lab of estelle bettelli, phd, showed that disease modifying therapies, or dmts, used to treat individuals with multiple sclerosis significantly changed the immune responses generated by covid-19 vaccines. In the future, this data could inform best approaches against covid-19, not only for people with autoimmune diseases or those who are immunocompromised, but for everyone.continued
Fundamental immunologythe center for fundamental immunology (cfi) investigates the human immune system to understand how it works in health and disease. at bri, we employ a variety of methods to examine the immune system function at the genetic, molecular and cellular levels. These include developing novel model systems of autoimmune and inflammatory disease, used to determine how activities of the immune system are regulated and how regulatory mechanisms break down in autoimmunity, allergy, asthma and covid-19. We also leverage samples from healthy subjects and patients with immune-mediated diseases to study immune system function and identify potential therapeutic targets. Peter morawski, phd, whose work involves how immune cells communicate with and influence the tissues that they reside in, was promoted to assistant member in the cfi.genetics and autoimmune disease riska team of bri researchers led by john ray, phd, along with collaborators at the jackson laboratory and the broad Institute, brought us closer to unraveling genetic mechanisms behind disease risk. The team analyzed genome-wide association studies (gwas) data from studies of type 1 diabetes, rheumatoid arthritis, ulcerative colitis, crohn's disease and ms, and identified 60 gene variants by assessing their influence on gene activity in t cells. They zeroed in on non-coding variants associated with the autoimmune disorders, one of which appears to play a key role in keeping the immune system's t cells in check.
Translational immunologythe center for translational immunology (cti) involves observations in the basic Research lab, which are then quickly tested in the clinic with patients, with results brought back to the lab again in an expedient and systematic way. This type of Research "translates" new methods to improve our ability to predict disease risk, prevent onset of disease, slow disease progression and improve safety and efficacy of treatments. at bri, translational Research addresses autoimmune and immune-mediated diseases.the bri biorepository is a collection of blood, serum and tissue samples, as well as medical histories, from volunteers with and without diseases involving the immune system. Bri scientists and physician collaborators work together to study tissue, blood and serum samples along with the medical and demographic data. Bri's biorepository samples date back to 2000 and include multiple disease categories and a biorepository of healthy people for purposes of comparison.in april, soo jung yang, phd, was named Research assistant member in the cti. Dr. yang, who was previously a staff scientist in dr. buckner's Research lab, leads work on engineered tregs regulatory t cells, known to help protect against autoimmune disease and exploring new Research questions that stem from this work.autoimmune disease Research in the down syndrome populationin october, the national Institute of allergy and infectious diseases (niaid) announced a new $3.4 million-dollar five-year Research project grant (r01) to bri to study why immune response are altered in those with down syndrome (ds).bernard khor, md, phd, in partnership with Virginia Mason pediatrician rebecca partridge, md, will lead the r01 grant that builds on his prior findings that any given person with ds has an immune system that resembles that of a significantly older individual without ds. With this grant, he will examine the mechanisms behind advanced immune aging and explore how this impacts clinically relevant responses, such as the ability to mount an effective response to vaccination. His work is made possible by the bri biorepositories of blood and tissue samples from people with ds.in his previous studies, dr. khor and his team used mass cytometry to examine the immune systems of 28 people with ds and, through the creation of a new analytical software, showed how these immune systems share characteristics with those of much older subjects who do not have ds, as well as with individuals with certain autoimmune diseases. For the first time, a protein called il-6 was associated with changes that drive aging of the immune system.the team believes their findings may also help explain why people with ds are more likely to develop autoimmune diseases such as type 1 diabetes, celiac disease and rheumatoid arthritis.
Bri oversees the clinical Research program at Virginia Mason medical center, uniquely combining the expertise of a world-renowned medical Research Institute with the care of a healthcare quality leader.the clinical Research program supports Virginia Mason clinical investigators in studies across a wide variety of autoimmune and immune-mediated diseases and conditions, as well as a broad range of other diseases such as cancer and cardiac disease. The clinical Research program staff annually enrolls approximately 1500 study participants into Virginia Mason trials.

Grants made by Benaroya Research Institute at Virginia Mason

GranteeGrant descriptionAmount
University of California San Francisco / Ucsf Payroll OfficeMedical Research$7,518,752
Icahn School of Medicine at Mount SinaiMedical Research$2,474,889
Johns Hopkins University (JHU)Medical Research$2,055,090
...and 48 more grants made totalling $23,516,619

Who funds Benaroya Research Institute at Virginia Mason

Grants from foundations and other nonprofits
GrantmakerDescriptionAmount
Virginia Mason Medical CenterOperating Support$8,861,783
Virginia Mason Health SystemResearch Support$5,718,624
Seattle Children's HospitalPediatric Medical Research Grant Subaward$798,369
...and 28 more grants received totalling $17,527,218

Personnel at Benaroya Research Institute at Virginia Mason

NameTitleCompensation
Gary KaplanDirector , Chief Executive Officer VMFH$2,366,321
Ketul PatelBoard Member$3,565,171
Michael LabosierChief Financial Officer, Accounting$218,712
Mary RoyChief Administrative Officer , Immune Tolerance Network
Bolong CaoChief of Business Development$210,405
...and 24 more key personnel

Financials for Benaroya Research Institute at Virginia Mason

RevenuesFYE 06/2022
Total grants, contributions, etc.$78,966,995
Program services$5,286,187
Investment income and dividends$9,704,684
Tax-exempt bond proceeds$0
Royalty revenue$0
Net rental income$708,469
Net gain from sale of non-inventory assets$194,941
Net income from fundraising events$0
Net income from gaming activities$0
Net income from sales of inventory$0
Miscellaneous revenues$0
Total revenues$94,861,276

Form 990s for Benaroya Research Institute at Virginia Mason

Fiscal year endingDate received by IRSFormPDF link
2022-062023-05-15990View PDF
2021-062022-07-11990View PDF
2020-122021-11-17990View PDF
2019-122021-02-26990View PDF
2018-122020-01-14990View PDF
...and 9 more Form 990s
Data update history
July 21, 2023
Posted financials
Added Form 990 for fiscal year 2022
July 18, 2023
Updated personnel
Identified 32 new personnel
July 13, 2023
Used new vendors
Identified 4 new vendors, including , , , and
June 27, 2023
Posted financials
Added Form 990 for fiscal year 2020
May 31, 2023
Updated personnel
Identified 5 new personnel
Nonprofit Types
Medical research organizationsResearch centersCharities
Issues
Science and technologyHealthDiseases and disorders
Characteristics
Provides grantsConducts researchLobbyingOperates internationallyReceives government fundingTax deductible donations
General information
Address
1201 Ninth Ave
Seattle, WA 98101
Metro area
Seattle-Tacoma-Bellevue, WA
County
King County, WA
Website URL
benaroyaresearch.org/ 
Phone
(206) 342-6500
Facebook page
BenaroyaResearch 
IRS details
EIN
91-0653422
Fiscal year end
June
Taxreturn type
Form 990
Year formed
1956
Eligible to receive tax-deductible contributions (Pub 78)
Yes
Categorization
NTEE code, primary
H90: Medical Specialty Research
NAICS code, primary
5417: Scientific Research and Development Services
Parent/child status
Independent
Free account sign-up

Want updates when Benaroya Research Institute at Virginia Mason has new information, or want to find more organizations like Benaroya Research Institute at Virginia Mason?

Create free Cause IQ account